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Abstract
There is significant evidence arising from experimental models that
autoantibodies play a key role in the pathogenesis of inflammatory
arthritis. In addition to autoantibody production, B cells efficiently
present antigen to T cells, produce soluble factors, including cyto-
kines and chemokines, and form B cell aggregates in the target
organ of rheumatoid arthritis. In this review we analyze the multi-
faceted role that B cells play in the pathogenesis of rheumatoid
arthritis and discuss how this information can be used to guide
more specific targeting of B cells for the therapy of this disease.
Introduction
The advent of biological therapy has provided a powerful tool
to improve our understanding of the pathogenesis of disease.
As well as benefiting patients, the success of targeted
biological therapies demonstrates the importance of particular
molecules or cells in disease pathogenesis. The potent
efficacy of rituximab, a B-cell depleting agent, in the treatment
of patients with rheumatoid arthritis (RA) has revitalized
interest in the central role played by B cells in disease
pathogenesis [1] (Fig. 1).
Accumulation of B cells in the synovium is
driven by a variety of signals
RA is one of only a few diseases in which ectopic germinal
centre-like structures can be observed at the site of
inflammation [2]. These structures, which range from loose
aggregates of T and B cells to distinct follicle-like structures,
are often observed in close contact with the inflamed synovial
membrane of RA patients. A variety of cells, including fibro-
blast-like synoviocytes and dendritic cells, that are present in
the synovium of patients with RA produce factors that affect
B-cell survival, organization and trafficking, such as B cell-
activating factor of the TNF family (BAFF), CXC chemokine
ligand (CXCL)13, CXCL12 and lymphotoxin beta (Table 1)
[2-4]. Based on their immunological function and location,
each of these factors could contribute to the recruitment and
maintenance of B cells in arthritic joints, thus representing
potential therapeutic targets. For example, blockade of
surface lymphotoxin using a decoy lymphotoxin receptor-
immunoglobulin and BAFF, as discussed below, are currently
in clinical trials. Interestingly, the efficacy observed in RA
patients treated with etanercept, which binds to lymphotoxin-
α as well as tumour necrosis factor (TNF)-α, may partly be
related to blockade of the former cytokine [5]. Simultaneous
blockade of more than one factor that drives B-cell
accumulation may be a more efficient therapeutic approach
than targeting a single cytokine or chemokine.
The role played by B cells in the maintenance of ectopic
germinal centre-like structures, as well as in the immune
response in RA synovium, has been addressed by using a
humanized experimental model in which synovial tissue
derived from patients was implanted into severe combined
immunodeficient (SCID) mice [6]. B cells were then depleted
by administration of anti-CD20 (rituximab), and T-cell
responses were measured. The removal of B cells led to
disruption of the lymphoid-like structures and to a reduction
in T-helper (Th)1 interferon-γ producing cells, which are
known to be involved in the induction and maintenance of the
proinflammatory cytokine cascade.
Role played by B cells as antigen-presenting
cells in rheumatoid arthritis
B cells actively participate in an autoimmune process through
interaction with T cells by a variety of mechanisms, including
antigen presentation and cytokine production. B cells process
antigens, which are presented to T cells via major
histocompatibility complex class II. Inherited susceptibility to
RA has been associated with DRB1 genes that encode the
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HLA-DR4 and HLA-DR1 molecules [7]. These findings
suggest a pathogenic role for antigen presentation in RA.
Although dendritic cells are believed to be important in
priming naïve T cells, B cells represent the predominant
population of antigen-presenting cells in later phases of the
immune response [8]. Rheumatoid factor (RF)-producing B
cells are particularly effective in presenting immune
complexes to T cells, irrespective of the antigen contained in
the antigen-antibody complex [9]. Thus, T cells of other
specificities could easily be activated if immune complexes in
RA contain other antigens.
T-cell priming by B cells has been shown to be important in the
pathogenesis of a murine model of arthritis. Specifically, the
involvement of B cells in priming T cells was dissected within
the context of proteoglycan (PG)-induced arthritis by using a
mouse deficient in a secretory antibody (mIgM) [10]. These
mice express a membrane-bound heavy chain transgene,
which pairs with an endogenous light chain specific for hapten
4-hydroxy-3-nitro-phenyl acetyl (NP). T cells isolated from PG-
immunized mIgM mice failed to induce arthritis in SCID mice,
even if they were co-transferred with wild-type B cells,
suggesting that T cells do not become properly primed in this
experimental setting. However, targeting PG to B cells using
NP coupled with PG led to differentiation of arthritogenic T
cells that are able to transfer disease. Other antigen-presenting
cells could not substitute for B cells in this T-cell priming,
supporting a central role for B cells in driving autoreactive T
cells. Autoantibody production was also essential for
development of severe disease, indicating that B cells play two
complementary roles in the pathogenesis of arthritis.
Immune complexes can activate B cells via
Toll-like receptor ligands
It was recently shown that chromatin-containing immune
complexes can activate B cells through Toll-like receptor
Figure 1
B cell participation in RA. Illustrated is the potential role of B cells in the regulation of immune responses in RA. Mature B cells, upon antigen
encounter and TLR stimulation, expand and differentiate into short-lived plasma cells or can enter into a GC reaction, which is necessary for the
generation of both memory B cells, and long-lived plasma cells that can produce autoantibodies. Autoantibodies form immune complexes that
further activate the immune system via Fc and complement receptors expressed on target cells. Antigen-activated mature B cells provide help to T
cells and induce differentiation of effector T cells that produce proinflammatory cytokines (known to be directly/indirectly involved in cartilage and
bone destruction). Mature B cells, via mechanisms yet to be elucidated, can also differentiate into IL-10 producing B cells that can dampen the
autoreactive T-cell response. GC, germinal centre; IFN, interferon; IL, interleukin; RA, rheumatoid arthritis; TLR, Toll-like receptor ligand; TNF,
tumour necrosis factor.Page 3 of 6
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ligand (TLR)9. These immune complexes activate B cells to
produce RF by synergistic engagement of B-cell receptor
and TLR9 [11]. TLRs were originally described as a family of
pattern-recognition receptors that can differentiate between
microbial molecular patterns and host components [12]. Their
engagement results in rapid activation of the innate and
adaptive immune systems to effect clearance of pathogens.
There is mounting evidence suggesting involvement of TLR
signalling in the pathogenesis of experimental arthritis. Mice
deficient for MyD88, the essential adaptor molecule involved
in signalling by TLR family members, failed to develop
streptococcal cell wall induced arthritis, and TLR2-deficient
mice exhibited reduced disease [13]. Furthermore, direct
injection of CpG DNA or double-stranded RNA into joints of
susceptible mice results in the development of transient
arthritis [14]. Heat shock protein, fibrinogen and hyaluronan,
which are known to bind to TLR4, have all been detected in
the inflamed joint [15]. In the KB×N model of murine antibody
transferred arthritis, TLR4-deficient mice exhibit reduced
disease [16]. Although there is enough evidence from
experimental arthritis implicating TLRs in the development of
arthritis, whether TLR activation is involved in human RA
remains to be formally demonstrated.
Autoantibodies as effector molecules in
rheumatoid arthritis
The pathological involvement of antibodies in inflammatory
arthritis was first proved using DBA/1 mice immunized with
collagen type II in complete Freund’s adjuvant (CFA). These
mice develop a severe arthritis that shares some pathological
features with human RA. It has been demonstrated that SCID
mice (which lack T and B cells), when treated with serum
isolated from arthritic DBA/1 mice, develop an inflammatory
arthritis [17,18]. However, the disease was transient and less
severe than collagen-induced arthritis (CIA). A more severe
arthritis can be induced in recipient mice if serum is
cotransferred with T cells presensitized with heat denatured
collagen [19].
The pathological relevance of B cells in arthritis was further
demonstrated by Holdhmal and colleagues [20], using µMT
mice (which lack B cells) immunized with type II collagen in
CFA. Lack of B cells completely prevented induction of
arthritis and resulted in an impaired T-cell response to type II
collagen (Mauri C, unpublished data); this suggests that
although autoantibodies can initiate disease, other compo-
nents of the immune system are needed to fuel the
pathogenic response.
Compared with evidence from experimental models of
arthritis, proof that antibodies are also pathogenic in human
RA is more difficult to obtain. The presence of RF in serum,
which binds to the constant region of IgG, was first identified
in 1957 [21] and has long been recognized as a marker in
the majority of patients with RA. The severity of RA has been
correlated with RF levels, and patients who are seropositive
for RF have more aggressive disease and worse prognosis
[22,23]. Important studies have indicated that the presence
of RF can be detected many years before arthritis begins
[24,25].
The possible pathogenic role of RF-positive B cells has been
revisited with the increased use of rituximab in RA therapy. RF
can cause tissue damage through formation of immune
complexes, by activation of complement, thereby recruiting
cells into the synovium. Although preliminary data suggested
that patients who are RF negative appear less likely to
respond to B-cell depletion therapy [26], a larger trial [27] did
not identify substantial differences in the response between
RF-positive and RF-negative patients with RA. However, RF
titres fell by 55% in those patients who were RF positive,
which corroborates previous findings [28]. Moreover, routine
assays for RF are not particularly sensitive and do not exclude
their presence. Thus, patients identified as being RF-negative
may still have low titres of RF. It is also possible that the many
other autoantibody specificities present in patients with RA
may distinguish those patients who respond to rituximab.
These other autoantibody specificities include those directed
toward the nuclear antigen RA-33 and heavy chain binding
protein, both of which are found in early RA and pre-disease
sera [29]. Antibody and T-cell reponses to heavy chain binding
protein have been identified both in patients with RA and in
animal models, suggesting that this may be an important
autoantigen. Although antibodies to type II collagen have been
shown to induce disease in animal models, it is unlikely that
anti-collagen antibodies are relavant to human disease.
Recently, antibodies to citrulline-modified peptides (anti-
cyclic citrullinated peptide [CCP] antibodies) have attracted
Available online http://arthritis-research.com/content/9/2/205
Table 1
Potential targets driving B cell accumulation in the synovium 
Target Function
CXCL12 (SDF-1) B cell and plasma cell chemoattractant
CXCL13 B cell chemoattractant
Lymphotoxin-β Organization of B cells within lymphoid 
architecture
Induction of CXCL13
IL-5, IL-6, TNF-α Promote plasma cell accumulation and 
survival
BAFF Immature and mature B cell survival and 
proliferation
APRIL Mature B cell and plasma cell survival
TNF-α and IFN-γ Induces B cell release from bone marrow
Increased production of BAFF and APRIL
APRIL, a proliferation-inducing ligand; BAFF, B cell-activating factor of
the TNF family; CXCL, CXC chemokine ligand; IFN, interferon; 
IL, interleukin; TNF, tumour necrosis factor.considerable attention, and their measurement has now
entered into routine clinical use. From a clinical perspective,
anti-CCP antibodies represent a useful test for predicting
which patients with early arthritis will go on to develop RA.
The presence of both anti-CCP antibodies and RF predicts
the development of RA in patients with early arthritis with
high sensitivity and specificity [25]. The importance of anti-
CCP antibodies is further emphasized by their link with HLA-
DRB1 shared epitope alleles, the most important genetic risk
factor for RA. Recent work has suggested that this HLA
genetic risk factor is linked to the development of anti-CCP
antibodies rather than to the disease itself [30]. Thus, the
presence of these autoantibodies in RA, often preceding
disease by many years, may indicate a breakdown in central
and/or peripheral tolerance.
The pathological role played by anti-CCP antibodies was
recently confirmed in the CIA arthritis model. As in human RA,
anti-CCP antibodies can be detected before the onset of
disease and are present in inflamed synovium of mice in the
acute phase of CIA. Although the amount of anti-CCP
antibodies measured in serum of mice with acute
inflammation is similar to levels of antibodies to collagen type
II, transfer of anti-CCP antibodies alone failed to induce
disease in recipient mice. However, transfer of anti-CCP
antibodies to SCID mice significantly reduced the amount of
anti-collagen type II antibodies necessary to induce disease,
demonstrating a contributing role in the development of
arthritis [31]. The relevant targets of these antibodies in joints
or in peripheral tissue remain unknown.
Are both Fc receptors and complement
component C5a required for autoantibodies
to drive the effector phase in arthritis?
Antibodies can act directly on target organs and induce
disease through Fc-mediated activation of the complement
system or through the formation of immune complexes. In
addition, antibodies can directly activate Fcγ receptors
(FcγRs) expressed on both myeloid and lymphoid cells. A
clear insight into how antibodies work in arthritis has been
gleaned from the K/B×N model of RA. In these mice glucose-
6-phosphate isomerase (GPI) is the target autoantigen, and
T-cell reactivity to this ubiquitous antigen results in
recruitment of anti-GPI B cells and subsequent immune
complex-mediated arthritis [32,33]. Arthritis can be induced
in non-autoimmune recipients, or in RAG2-/- mice (which lack
both T and B cells), by transfer of sera or purified antibodies.
Similar to the SCID model mentioned above, inflammation
begins to subside between 15 and 30 days after antibody
transfer. Histologically, analysis of joints 30 days after transfer
revealed less inflammation than in the K/B×N model itself,
and little cartilage damage, supporting the notion that other
abnormalities in cellular types and soluble factors are needed
for full expression of disease [32]. FcγRs are intimately
involved in the pathogenesis of this arthritis. In particular,
much milder arthritis was observed in mice lacking the FcγRIII
receptor [34], whereas FcγRII-deficient mice exhibited acce-
lerated disease.
The involvement of FcγRIIB in mediating antibody damage
has also been investigated in the CIA model of arthritis.
FcγRIIB is an inhibitory receptor that suppresses B cells,
mast cells and macrophages, and transmits its inhibitory
signal via its immunoreceptor tyrosine-based inhibitory motif.
Deletion of FcγRIIB renders DBA/1 mice more susceptible to
disease [35]. Recently, the pathogenicity of human RA-
associated antibodies was also tested in a passive transfer
model using FcγRIIB deficient mice. Transfer of serum from
active RA patients, or an immunoglobulin-rich fraction, to 8- to
12-week-old B6.FcγRIIB-/- mice induced a mild transient
arthritis [36], indicating that serum from patients with RA can
induce an inflammatory arthritis. The administration of a large
amount of intravenous IgG (IVIG) is a common treatment for a
number of autoimmune conditions and is thought to modulate
Fc receptor function [37]. IVIG has been shown to have a
protective effect in the K/B×N mouse model of arthritis
discussed above through induction of FcγRIIB [38]. This
property of IVIG has been linked to sialylation of the Fc
portion of IgG. The proportion of sialylated IgG molecules in
commercial IVIG may account for the very mixed results
obtained when patients with RA were treated with IVIG [39].
Involvement of the complement system in the development of
mouse models of arthritis caused by autoantibodies has been
demonstrated using C5-deficient mice. Both the K/B×N and
collagen-induced model of arthritis are dependent on C5a for
disease expression, and antibodies to C5 ameliorated
disease in the K/B×N model [40,41]. This has led to clinical
trials of C5a receptor based peptides in RA, with mixed
results. Other components of the complement system such
as C4 do not participate in disease pathogenesis [40].
Therefore, the effector function of arthritogenic antibodies
rely both on Fc receptors and C5a.
Immunoregulation by B cells
Although the pathogenic role played by mature B cells in RA
has been extensively studied, new data have demonstrated
that a distinct subset of B cells, namely those that produce
IL-10, are involved in the downregulation of the immune
system. It was originally demonstrated that B-cell-deficient
mice developed an exacerbated experimental autoimmune
encephalomyelitis as compared with wild-type animals,
suggesting a protective role for B cells in the development of
autoimmune disease [42]. B cells that produce cytokines,
and in particular IL-10, have been reported to play an
immunoregulatory role in autoimmunity, chronic inflammatory
bowel disorders, asthma and infectious diseases [43,44]. In
the context of arthritis, we previously showed that stimulation
of splenic B cells isolated during the acute phase of disease,
with an agonistic anti-CD40 antibody, induces differentiation
of IL-10 producing B cells. Transfer of anti-CD40 stimulated
B cells to DBA/1 mice immunized with collagen type II in CFA
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which this subset of B cell regulates the immune response
against autoantigens are not fully understood. However, we
showed that mice treated with anti-CD40 challenged B cells
exhibit an impaired Th1 response [45]. Therefore one
plausible explanation is that production of IL-10 might restore
the dysregulated Th1/Th2 balance, or it could directly
modulate effector cells, including macrophages and dendritic
cells, thus downmodulating inflammatory responses. IL-10
producing B cells could also act as secondary antigen-
presenting cells, leading to an abortive response and
induction of anergic CD4+ T cells, or they could recruit
regulatory T cells or induce their differentiation. If an
equivalent population exists in humans, then removal of these
B cells by rituximab might be detrimental.
Targeting bad B cells
An understanding of which B cells are relevant to the
pathogenesis of disease is important in designing therapeutic
strategies to target B cells. The vast majority of B cells found
in peripheral blood are removed by rituximab, but the extent
and nature of B cell removal in other tissues in RA patients
remain to be established. For example, experiments
conducted in monkeys revealed that B cells residing in
tissues are less effectively removed, and that memory B cells
are more resistant to depletion than naïve ones [46]. Similar
observations have been made in murine studies using anti-
CD20, where marginal zone B cells, B1 cells and germinal
centre B cells are more resistant to depletion [47-49]. As
mentioned above, it is likely that plasma cells that producing
RF are likely to be important in disease pathogenesis, but
their depletion by rituximab is hampered by lack of CD20
expression. However, those plasma cells that have a short life
span rely on CD20-expressing B cell precursors for
continued renewal. Examination of peripheral blood indicates
that CD19+CD20- plasmablasts decrease following rituximab
therapy [50]. The observation that RF titres decrease
following rituximab treatment suggests that short-lived, rather
than long-lived, plasma cells are at least partly responsible for
their formation. A number of factors are known to be
important in plasma cell survival, including cytokines such as
TNF-α and the cell adhesion molecule CD44 [51]. Perhaps
use of anti-TNF-α together with rituximab may have syner-
gistic benefit through their combined targeting of B cells and
plasma cells, although infection-related side effects may
prohibit use of this combination.
Antagonists to BAFF also lead to incomplete removal of
peripheral and lymphoid B cells in monkeys, with marginal
zone-like B cells being particularly susceptible to depletion
[52]. Trials have begun to evaluate the anti-BAFF agent
belimumab (LymphoStat-B; Human Genome Sciences,
Rockville, MD, USA) in RA and have demonstrated limited
efficacy, perhaps because of incomplete blockade or
because other related B-cell survival factors such as a
proliferation-inducing ligand (APRIL) would not be affected.
Conclusion
Renewed interest in B cells in RA has been initiated by a
global B-cell-depleting agent, but it is likely that only a small
proportion of B cells contribute to disease pathogenesis
whereas others may actually be protective. It is hoped that
research in patients with RA using these new agents will
reveal correlations between pathogenic B cell subsets and
improvement in clinical disease activity, thereby enhancing
our understanding of the role played by B cells in human
disease.
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